Free Trial

NovoCure Q1 2024 Earnings Report

NovoCure logo
$29.66 -0.53 (-1.76%)
As of 01/6/2025 04:00 PM Eastern

NovoCure EPS Results

Actual EPS
-$0.36
Consensus EPS
-$0.43
Beat/Miss
Beat by +$0.07
One Year Ago EPS
-$0.50

NovoCure Revenue Results

Actual Revenue
$138.50 million
Expected Revenue
$131.44 million
Beat/Miss
Beat by +$7.06 million
YoY Revenue Growth
+13.30%

NovoCure Announcement Details

Quarter
Q1 2024
Time
Before Market Opens

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

NovoCure Earnings Headlines

Novocure price target raised to $46 from $34 at Evercore ISI
Boost Your 2025 Income with Just $30
Are you ready to start 2025 with a steady income stream from stocks priced under $30? Our latest guide introduces you to straightforward and effective options strategies tailored for everyday investors in 2025. With clear, step-by-step insights, you’ll discover how to turn well-known companies like Ford and Intel into reliable sources of monthly income. No complicated charts. No Wall Street jargon. Just actionable strategies that work in the current market landscape.
Novocure Limited Share Price (NVCR.US)
Novocure Limited Share Price (NVCR.US)
See More NovoCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NovoCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NovoCure and other key companies, straight to your email.

About NovoCure

NovoCure (NASDAQ:NVCR), an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

View NovoCure Profile

More Earnings Resources from MarketBeat